Multiple Sclerosis Drugs Market Size is projected to reach

New York, United States, March 08, 2023 (GLOBE NEWSWIRE) -- Multiple sclerosis (MS) is an immune-mediated central nervous system disorder. Demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy, and neuroaxonal loss characterize this condition. The increasing frequency of multiple sclerosis has increased the global demand for effective diagnosis and treatment. Governments around the world actively support multiple sclerosis drug discovery and treatment. The expansion of the multiple sclerosis medications market can be ascribed to the key market players' growing emphasis on R&D to produce innovative drugs. In addition, the introduction of new products, the expansion of government programs to increase treatment accessibility, and the rising incidence of multiple sclerosis are anticipated to contribute to the market growth.

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/multiple-sclerosis-drugs-market/request-sample

Rising R&D and Government Initiatives Drive the Market

Rapid advancements in the healthcare industry, an increase in the number of prospective pipeline drug development projects, and unmet needs associated with MS are some of the factors driving market expansion. Multiple governments and non-governmental organizations, including the National Multiple Sclerosis Society, the Multiple Sclerosis Association of America, the Multiple Sclerosis Foundation, UCSF Health, and the European Multiple Sclerosis Platform, are actively working to raise awareness about MS and are funding R&D activities for the development of novel drugs. Consequently, advancements in the pharmaceutical business, increased government financing, and rising investment in the healthcare and medical industry are driving market expansion.

Report Scope

Report Metric	Details
Market Size	USD 34.03 Billion by 2031
CAGR	3.7% (2023-2031)
Historical Data	2020-2021
Base Year	2022
Forecast Period	2023-2031
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Drug Class, By Route of Administration, By Distribution Channel, By Regions
Geographies Covered	North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors	Pfizer, Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Acorda Therapeutics Inc., Biogen Inc., Johnson & Johnson, EMD Serono, Eisai Co. Ltd., Apitope, AbbVie Inc.
Key Market Opportunities	The increasing prevalence of MS will create lucrative opportunities for the market in the years to come
Key Market Drivers	Upsurge in R&D and Rising Government Initiatives Robust Product Pipeline and Increasing FDA Approvals

Buy Now Full Report @ https://straitsresearch.com/buy-now/multiple-sclerosis-drugs-market

Regional Analysis

North America is leading the global multiple sclerosis drugs market. The increasing prevalence of multiple sclerosis, the developing healthcare infrastructure, and the escalating healthcare expenditures in the United States and Canada are driving the market expansion. Market expansion is being driven by the increasing concentration of pharmaceutical companies engaged in R&D operations for the development of innovative MS treatments. The reimbursement programs in the United States and Canada are increasing the treatment's uptake. As per the National Multiple Sclerosis Society, MS affects around 291 per 100,000 people in Canada. In the United States, however, MS affects 450 000 people. In addition, the National Multiple Sclerosis Society (NMSS) and the Multiple Sclerosis Association of America (MSAA) are actively educating the public about MS symptoms and cutting-edge treatments. Similar to the unmet demands in the clinical segment, the main players are actively working to meet the increased need for highly effective and swiftly acting-drugs.

Europe is predicted to be the second in the global multiple sclerosis drug market on account of the increasing prevalence of MS. According to the European Multiple Sclerosis Platform (EMSP), around 600,000 persons in Europe have MS. The market is driven by increased government support, rising healthcare expenditure on MS, soaring investments in R&D of MS medications and clinical research, and growing knowledge of enhanced treatment alternatives. During the forecast period, the United Kingdom is predicted to hold a large share of the multiple sclerosis drug market. Increases in the older population, healthcare costs, and research and development activities contribute to market expansion. On the other hand, emerging nations in the region, such as France, Italy, and Spain, are projected to grow at an encouraging rate over the forecast period.

In Asia Pacific, the multiple sclerosis drugs market is majorly driven by a large pool of patients suffering from MS in China and Japan, the launch and approval of new products, and growing investments by leading market players. The government is actively working to develop the healthcare infrastructure and is increasing its healthcare expenditure for the same. Additionally, leading players in the region are engaging in agreements with local drug manufacturers to develop technologically advanced products. Moreover, the well-improved distribution network in pharma-emerging nations is also supporting the regional market.

The Middle East and Africa regions are anticipated to exhibit moderate expansion. In Africa, the lack of understanding regarding MS treatment choices, the high cost of medications, and the underdevelopment of medical facilities are the issues impeding market expansion. However, the rising frequency of MS will generate business opportunities in the coming years. Due to the rising prevalence of the disease in Latin America, the government has been obligated to issue guidelines and recommendations for disease prevention. Government agencies are conducting a number of public awareness campaigns to educate patients on the many treatment options available. In addition, as health expenditures per capita increase, product demand will increase, accelerating the expansion of the Latin American market for multiple sclerosis medications. However, the high cost of multiple sclerosis medicines would hinder the growth rate of multiple sclerosis pharmaceuticals over the forecast period.

Key Highlights

The global multiple sclerosis drugs market size is projected to reach USD 34.03 billion by 2031, growing with a CAGR of 3.7% during the forecast period (2023–2031).
On the basis of drug class, the market is segmented into immunomodulators, immunosuppressants, interferons, and others. The immunomodulators segment is dominating the global multiple sclerosis drugs market.
By route of administration, the market is segmented into oral, injectable, and infusions. The injectable segment is the fastest-growing segment.
Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment is predicted to dominate the market.
North America is leading the global multiple sclerosis drugs market.

The global MS drugs market is consolidated with the presence of

Pfizer, Bayer AG
Teva Pharmaceutical Industries Ltd
Novartis AG
Sanofi
F. Hoffmann-La Roche Ltd
Celgene Corporation
Acorda Therapeutics, Inc
Biogen, Inc
Johnson & Johnson
EMD Serono
Eisai Co., Ltd.
Apitope
AbbVie, Inc.

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/multiple-sclerosis-drugs-market/request-sample

Global Multiple Sclerosis Drugs Market Segmentation

By Drug Class

Immunomodulators
Immunosuppressants
Interferons
Others

By Route of Administration

Oral
Injectables
Infusions

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Stores

By Regions

North America
Europe
Asia-Pacific
LAMEA

Table of Content

EXECUTIVE SUMMARY
RESEARCH SCOPE & SEGMENTATION
1. Research Objectives
2. Market Definition
3. Limitations & Assumptions
4. Market Scope & Segmentation
5. Currency & Pricing Considered
MARKET OPPORTUNITY ASSESSMENT
1. Emerging Regions / Countries
2. Emerging Companies
3. Emerging Applications / End Use
4. Investment Landscape
5. New Business Models / Revenue Streams
6. TAM
MARKET TRENDS
1. Drivers
2. Market Warning Factors
3. Latest Macro Economic Indicators
4. Geopolitical Impact
5. Human Factors
6. Technology Factors
MARKET ASSESSMENT
1. Porters Five Forces Analysis
2. Value Chain Analysis
3. Raw Material Analysis
4. Sales And Distribution Channel Analysis
5. Trade Analysis
6. Average Pricing Analysis
7. Patent Analysis
8. M & A Agreements & Collabration Analysis
9. Export Import Analysis
10. Cost Structure Analysis
ESG TRENDS
GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET SIZE ANALYSIS
1. Global Multiple Sclerosis Drugs Market Introduction
2. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Immunomodulators
    1. By Value
  3. Immunosuppressants
    1. By Value
  4. Interferons
    1. By Value
  5. Others
    1. By Value
3. By Route Of Administration
  1. Introduction
    1. Route Of Administration By Value
  2. Oral
    1. By Value
  3. Injectables
    1. By Value
  4. Infusions
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Stores
    1. By Value
NORTH AMERICA MARKET ANALYSIS
1. Introduction
2. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Immunomodulators
    1. By Value
  3. Immunosuppressants
    1. By Value
  4. Interferons
    1. By Value
  5. Others
    1. By Value
3. By Route Of Administration
  1. Introduction
    1. Route Of Administration By Value
  2. Oral
    1. By Value
  3. Injectables
    1. By Value
  4. Infusions
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Stores
    1. By Value
5. U.S.
  1. By Drug Class
    1. Introduction
      1. Drug Class By Value
    2. Immunomodulators
      1. By Value
    3. Immunosuppressants
      1. By Value
    4. Interferons
      1. By Value
    5. Others
      1. By Value
  2. By Route Of Administration
    1. Introduction
      1. Route Of Administration By Value
    2. Oral
      1. By Value
    3. Injectables
      1. By Value
    4. Infusions
      1. By Value
  3. By Distribution Channel
    1. Introduction
      1. Distribution Channel By Value
    2. Hospital Pharmacy
      1. By Value
    3. Retail Pharmacy
      1. By Value
    4. Online Stores
      1. By Value
6. Canada
EUROPE MARKET ANALYSIS
1. Introduction
2. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Immunomodulators
    1. By Value
  3. Immunosuppressants
    1. By Value
  4. Interferons
    1. By Value
  5. Others
    1. By Value
3. By Route Of Administration
  1. Introduction
    1. Route Of Administration By Value
  2. Oral
    1. By Value
  3. Injectables
    1. By Value
  4. Infusions
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Stores
    1. By Value
5. U.K.
  1. By Drug Class
    1. Introduction
      1. Drug Class By Value
    2. Immunomodulators
      1. By Value
    3. Immunosuppressants
      1. By Value
    4. Interferons
      1. By Value
    5. Others
      1. By Value
  2. By Route Of Administration
    1. Introduction
      1. Route Of Administration By Value
    2. Oral
      1. By Value
    3. Injectables
      1. By Value
    4. Infusions
      1. By Value
  3. By Distribution Channel
    1. Introduction
      1. Distribution Channel By Value
    2. Hospital Pharmacy
      1. By Value
    3. Retail Pharmacy
      1. By Value
    4. Online Stores
      1. By Value
6. Germany
7. France
8. Spain
9. Italy
10. Russia
11. Nordic
12. Benelux
13. Rest Of Europe
APAC MARKET ANALYSIS
1. Introduction
2. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Immunomodulators
    1. By Value
  3. Immunosuppressants
    1. By Value
  4. Interferons
    1. By Value
  5. Others
    1. By Value
3. By Route Of Administration
  1. Introduction
    1. Route Of Administration By Value
  2. Oral
    1. By Value
  3. Injectables
    1. By Value
  4. Infusions
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Stores
    1. By Value
5. China
  1. By Drug Class
    1. Introduction
      1. Drug Class By Value
    2. Immunomodulators
      1. By Value
    3. Immunosuppressants
      1. By Value
    4. Interferons
      1. By Value
    5. Others
      1. By Value
  2. By Route Of Administration
    1. Introduction
      1. Route Of Administration By Value
    2. Oral
      1. By Value
    3. Injectables
      1. By Value
    4. Infusions
      1. By Value
  3. By Distribution Channel
    1. Introduction
      1. Distribution Channel By Value
    2. Hospital Pharmacy
      1. By Value
    3. Retail Pharmacy
      1. By Value
    4. Online Stores
      1. By Value
6. Korea
7. Japan
8. India
9. Australia
10. Taiwan
11. South East Asia
12. Rest Of Asia-Pacific
MIDDLE EAST AND AFRICA MARKET ANALYSIS
1. Introduction
2. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Immunomodulators
    1. By Value
  3. Immunosuppressants
    1. By Value
  4. Interferons
    1. By Value
  5. Others
    1. By Value
3. By Route Of Administration
  1. Introduction
    1. Route Of Administration By Value
  2. Oral
    1. By Value
  3. Injectables
    1. By Value
  4. Infusions
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Stores
    1. By Value
5. UAE
  1. By Drug Class
    1. Introduction
      1. Drug Class By Value
    2. Immunomodulators
      1. By Value
    3. Immunosuppressants
      1. By Value
    4. Interferons
      1. By Value
    5. Others
      1. By Value
  2. By Route Of Administration
    1. Introduction
      1. Route Of Administration By Value
    2. Oral
      1. By Value
    3. Injectables
      1. By Value
    4. Infusions
      1. By Value
  3. By Distribution Channel
    1. Introduction
      1. Distribution Channel By Value
    2. Hospital Pharmacy
      1. By Value
    3. Retail Pharmacy
      1. By Value
    4. Online Stores
      1. By Value
6. Turkey
7. Saudi Arabia
8. South Africa
9. Egypt
10. Nigeria
11. Rest Of MEA
LATAM MARKET ANALYSIS
1. Introduction
2. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Immunomodulators
    1. By Value
  3. Immunosuppressants
    1. By Value
  4. Interferons
    1. By Value
  5. Others
    1. By Value
3. By Route Of Administration
  1. Introduction
    1. Route Of Administration By Value
  2. Oral
    1. By Value
  3. Injectables
    1. By Value
  4. Infusions
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Stores
    1. By Value
5. Brazil
  1. By Drug Class
    1. Introduction
      1. Drug Class By Value
    2. Immunomodulators
      1. By Value
    3. Immunosuppressants
      1. By Value
    4. Interferons
      1. By Value
    5. Others
      1. By Value
  2. By Route Of Administration
    1. Introduction
      1. Route Of Administration By Value
    2. Oral
      1. By Value
    3. Injectables
      1. By Value
    4. Infusions
      1. By Value
  3. By Distribution Channel
    1. Introduction
      1. Distribution Channel By Value
    2. Hospital Pharmacy
      1. By Value
    3. Retail Pharmacy
      1. By Value
    4. Online Stores
      1. By Value
6. Mexico
7. Argentina
8. Chile
9. Colombia
10. Rest Of LATAM
COMPETITIVE ASSESSMENT
1. Adoption Matrix
2. Multiple Sclerosis Drugs Market Share By Manufacturers
3. Multiple Sclerosis Drugs Market Ranking By Revenue For Manufacturers
4. Average Price By Manufacturers
5. Vendor Footprint Analysis
MARKET PLAYERS ASSESSMENT
1. Pfizer
  1. Overview
  2. Business Information
  3. Revenue
  4. ASP
  5. Gross Margin
  6. Swot Analysis
  7. Recent Developmments
2. Bayer AG
3. Teva Pharmaceutical Industries Ltd.
4. Novartis AG
5. Sanofi
6. F. Hoffmann-La Roche Ltd.
7. Celgene Corporation
8. Acorda Therapeutics Inc.
9. Biogen Inc.
10. Johnson & Johnson
11. EMD Serono
12. Eisai Co. Ltd.
13. Apitope
14. AbbVie Inc.
RESEARCH METHODOLOGY
1. Research Data
  1. Secondary Data
    1. Major Secondary Sources
    2. Key Data From Secondary Sources
  2. Primary Data
    1. Key Data From Primary Sources
    2. Breakdown Of Primaries
  3. Secondary And Primary Research
    1. Key Industry Insights
2. Market Size Estimation
  1. Bottom-Up Approach
  2. Top-Down Approach
  3. Market Projection
3. Research Assumptions
  1. Assumptions
4. Limitations
5. Risk Assessment
APPENDIX
1. Discussion Guide
2. Customization Options
3. Related Reports
DISCLAIMER

Table of Content @ https://straitsresearch.com/report/multiple-sclerosis-drugs-market/toc

Market News

In June 2021, The European Commission authorized Aubagio (teriflunomide) to treat relapsing-remitting multiple sclerosis in children ages 10 to 17. The approval confirms Aubagio as the first oral medication for multiple sclerosis in children and adolescents in the European Union.
In March 2021, Janssen Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) approved PONVORY (ponesimod) for treating relapsing types of multiple sclerosis in adults.

News Media

Global Contraceptive Drugs Market Grows Steadily at a CAGR of 7.3%

Have a Look at the Related Research Report?

Anti-Inflammatory Therapeutics Market: Information by Drug Class (Nonsteroidal Anti-Inflammatory Drugs), Indication (Respiratory Diseases, Multiple Sclerosis), and Regions—Forecast till 2030

Active Wheelchair Market: Information by Product Type (Manual Wheelchairs, Power Wheelchairs), Indication (Alzheimer’s Disease, Multiple Sclerosis), and Region — Forecast till 2030

Generic Drugs Market: Information by Route of Administration (Oral, Topical, Injectable), Application (Cardiovascular Products, Anti-infective Drugs), Regions—Forecast till 2031

Ophthalmic Drugs Market: Information by Drug Class (Anti-Allergy, Anti-VEGF Agents), Disease (Dry Eye, Allergies), Administration (Topical, Systemic), and Region — Forecast till 2030

Dementia Drugs Market: Information by Indication (Lewy Body Dementia, Alzheimer's Disease, Vascular Dementia), Drug Class (MAO-B Inhibitors, Glutamate), and Regions-Forecast till 2030

About Straits Research Pvt. Ltd.

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

For more information on your target market, please contact us below:

Phone: +1 646 480 7505 (the U.S.)

+91 8087085354 (APAC)

+44 208 068 9665 (the U.K.)

Email: sales@straitsresearch.com

Follow Us: LinkedIn | Facebook | Instagram | Twitter

Multiple Sclerosis Drugs Market Size is projected to reach USD 34.03 Billion by 2031, growing at a CAGR of 3.7%: Straits Research

The global multiple sclerosis drugs market size was valued at USD 24.54 billion in 2022. It is projected to reach USD 34.03 billion by 2031, growing with a CAGR of 3.7% during the forecast period (2023–2031). North America is leading the global multiple sclerosis drugs market.

Tags

Multiple Sclerosis Drugs Market Size is projected to reach USD 34.03 Billion by 2031, growing at a CAGR of 3.7%: Straits Research

The global multiple sclerosis drugs market size was valued at USD 24.54 billion in 2022. It is projected to reach USD 34.03 billion by 2031, growing with a CAGR of 3.7% during the forecast period (2023–2031). North America is leading the global multiple sclerosis drugs market.

Tags

Related Links